Amplification and overexpression of the cyclin D1 gene in head and neck squamous cell carcinoma

X Wang, Z P Pavelic, Y-Q Li, L Wang, L Gleich, K Radack, J L Gluckman, P J Stambrook

Abstract

**Aims**—To determine cyclin D1 gene amplification and expression levels in head and neck squamous cell carcinoma (HNSCC) patients.

**Methods**—Total RNA and genomic DNA were isolated from 40 samples of HNSCC tissue and matched normal tissue and were hybridised with a cyclin D1 cDNA probe. Northern and Southern analyses were used to detect mRNA overexpression and cyclin D1 gene amplification, respectively.

**Results**—15 of the 40 HNSCC samples examined (38%) showed cyclin D1 gene amplification. Of these 15 samples, all 13 from which RNA was available showed increased cyclin D1 expression.

**Conclusions**—HNSCC patients with both amplification and overexpression of the cyclin D1 gene were at greater risk than patients who showed no cyclin D1 gene amplification; amplification and overexpression of the cyclin D1 gene may play an important role in the progression of HNSCC and in clinical outcome.

Keywords: cyclin D1, head and neck squamous cell carcinoma, gene amplification, mRNA overexpression, tumour progression.

Cyclins are central to the control of the eukaryotic cell cycle. When their expression is unregulated, they are considered likely participants in the oncogenic process. Within the cyclin gene family, the involvement of cyclin D1 in various human tumours has often been observed. Recently, the capacity of altered cyclin D1 gene expression to transform cells in vitro and in vivo has been demonstrated, indicating that cyclin D1 indeed plays an important role in tumorigenesis.

The deregulation of cyclin D1 in tumours occurs as a consequence of either tumour specific gene translocation or amplification of chromosome locus 11q13, where the cyclin D1 gene resides. In the case of parathyroid adenoma and some B cell lymphomas, the cyclin D1 gene undergoes rearrangement. In contrast, amplification of this gene has been implicated in other types of human tumours including those of breast, oesophagus, lung, liver and urinary bladder, and in head and neck squamous cell carcinomas (HNSCC).

Head and neck carcinomas account for 5-7% of new cases of cancer diagnosed annually and for about 3% of all cancer deaths. Over 90% of these tumours are squamous cell carcinomas. Epidemiological studies have indicated that tobacco is a major factor in the tumorigenesis of HNSCC, while alcohol, environmental exposure, and some viral infections may play a synergistic role. The molecular mechanisms operating in the malignant transformation of these carcinomas are still largely unknown. Although amplification of chromosome band 11q13, including int-2 and hst-1 genes, has been found in HNSCC, inconsistent and often absent expression of these genes suggests that they do not play a key role in oncogenesis. Another possible target gene in the HNSCC is the cyclin D1 gene, which is overexpressed in HNSCC cell lines. However, cyclin D1 gene expression in HNSCC patients has not been evaluated systematically in relation to clinical outcome.

In this study we have examined the relationship between gene amplification and mRNA overexpression of cyclin D1 in HNSCC patients. During the course of this work, a paper indicating that cyclin D1 gene amplification correlates with higher levels of mRNA in human laryngeal carcinoma was published. Our investigation confirms these results and further indicates a poor prognosis for patients with cyclin D1 gene amplification.

**Methods**

**PATIENTS AND TISSUES**

Forty human HNSCC tissue samples were collected from patients who underwent surgery between March 1992 and May 1994. Adjacent normal mucosa was also obtained from the same patient. Of the 40 HNSCC samples used in the study, 33 were primary and seven were recurrent carcinomas. The 33 primary HNSCCs included two stage II, nine stage III, and 22 stage IV carcinomas.

**DNA and RNA isolation**

Tissue was pulverised and ground to a fine powder with a pestle in a mortar partially filled with liquid nitrogen. Total RNA and high molecular weight DNA were isolated by guanidine isothiocyanate extraction and caesium chloride gradient centrifugation.
Cyclin D1 gene amplification in head and neck cancer

M257

Cyclin D1 gene amplification overexpression and clinicopathological characteristics of patients with primary head and neck squamous cell carcinoma (a total of 19 patients) who underwent surgery from March 1992 to July 1993

<table>
<thead>
<tr>
<th>No</th>
<th>Age/sex</th>
<th>Site</th>
<th>TNM</th>
<th>Clinical stage</th>
<th>Gene amplification</th>
<th>mRNA overexpression</th>
<th>*Alive/dead</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>69/M</td>
<td>Hypopharynx</td>
<td>T4N2M0</td>
<td>IV</td>
<td>+</td>
<td>+</td>
<td>Dead</td>
</tr>
<tr>
<td>4</td>
<td>65/F</td>
<td>Subglottic</td>
<td>T3N0M0</td>
<td>III</td>
<td></td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>5</td>
<td>54/F</td>
<td>Oral cavity</td>
<td>T4N2M2</td>
<td>IV</td>
<td>+</td>
<td>-</td>
<td>Unavailable</td>
</tr>
<tr>
<td>6</td>
<td>60/F</td>
<td>Oral cavity</td>
<td>T2N2M2</td>
<td>IV</td>
<td></td>
<td></td>
<td>Alive</td>
</tr>
<tr>
<td>7</td>
<td>76/M</td>
<td>Oropharynx</td>
<td>T2N1M0</td>
<td>III</td>
<td>-</td>
<td>-</td>
<td>Dead</td>
</tr>
<tr>
<td>8</td>
<td>57/M</td>
<td>Hypopharynx</td>
<td>T3N2M0</td>
<td>IV</td>
<td>+</td>
<td>+</td>
<td>Dead</td>
</tr>
<tr>
<td>9</td>
<td>74/M</td>
<td>Oral cavity</td>
<td>T3N0M0</td>
<td>III</td>
<td>+</td>
<td>+</td>
<td>Dead</td>
</tr>
<tr>
<td>11</td>
<td>49/M</td>
<td>Oral cavity</td>
<td>T4N0M0</td>
<td>IV</td>
<td>-</td>
<td>+</td>
<td>Alive</td>
</tr>
<tr>
<td>12</td>
<td>53/F</td>
<td>Subglottic</td>
<td>T3N0M0</td>
<td>III</td>
<td></td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>13</td>
<td>56/M</td>
<td>Parapharynx</td>
<td>T4N1M0</td>
<td>IV</td>
<td>+</td>
<td>+</td>
<td>Dead</td>
</tr>
<tr>
<td>16</td>
<td>56/M</td>
<td>Oropharynx</td>
<td>T4N2M2</td>
<td>IV</td>
<td>+</td>
<td>+</td>
<td>Dead</td>
</tr>
<tr>
<td>17</td>
<td>40/M</td>
<td>Supraglottic</td>
<td>T2N1M0</td>
<td>III</td>
<td></td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>18</td>
<td>72/M</td>
<td>Supraglottic</td>
<td>T2N2M0</td>
<td>IV</td>
<td>+</td>
<td>+</td>
<td>Dead</td>
</tr>
<tr>
<td>19</td>
<td>54/M</td>
<td>Oropharynx</td>
<td>T3N2M0</td>
<td>IV</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>21</td>
<td>71/M</td>
<td>Supraglottic</td>
<td>T2N0M0</td>
<td>II</td>
<td></td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>23</td>
<td>68/M</td>
<td>Hypopharynx</td>
<td>T4N1M0</td>
<td>IV</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>24</td>
<td>70/M</td>
<td>Oropharynx</td>
<td>T2N0M0</td>
<td>II</td>
<td></td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>26</td>
<td>47/M</td>
<td>Hypopharynx</td>
<td>T4N0M0</td>
<td>IV</td>
<td>+</td>
<td>+</td>
<td>Dead</td>
</tr>
<tr>
<td>27</td>
<td>60/M</td>
<td>Oropharynx</td>
<td>T3N1M0</td>
<td>IV</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
</tbody>
</table>

TNM: staging system for classification of head and neck cancers. Extent of primary cancer (T), status of regional lymph nodes (N), absence or presence of metastatic spread (M).

- +: with cyclin D1 gene amplification or mRNA overexpression; -: without gene amplification or overexpression.

*Alive: of surviving patients, follow up was 10 to 23 months (average 18 months).

SOUTHERN ANALYSIS

A 10 μg sample of genomic DNA was digested to completion with EcoRI (Life Technology). The digested DNA was then separated on 0.8% agarose gel and transferred to a Zetabind membrane (CUNO). The membrane was prehybridised at 65°C in 6× SSC (NaCl/sodium citrate), 5× Denhard’s solution, 0.5% sodium dodecyl sulphate (SDS) (wt/vol), and 100 mg/ml denatured salmon sperm DNA. The human cyclin D1 cDNA probe (provided by Dr D Beach) was labelled with 32P using a Prime-IT II random primer labelling kit (Strategene) and was added to the prehybridisation solution. After hybridisation, the membrane was washed twice with 2× SSC, 0.1% SDS at room temperature for 30 min, and twice with 0.1× SSC, 0.1% SDS at 60°C for 20–30 min. The membrane was then autoradiographed. After removing the cyclin D1 cDNA probe, the membrane was probed with a p53 cDNA probe (provided by Dr D Givol) as a single copy internal control to normalise possible variation in loading or transfer of DNA.

NORTHERN ANALYSIS

A 5 μg aliquot of total RNA from each sample was fractionated on a 1.2% agarose gel after denaturing with glyoxal/dimethylsulphoxide. The RNA was transferred and hybridised as described above. Washes of membranes were carried out at room temperature in 1× SSC, 0.1% SDS for 15 min twice, and at 60°C in 0.2× SSC, 0.1% SDS for 20 min twice. The human β actin cDNA probe was used as an internal control for northern analysis.

Results

The cyclin D1 cDNA probe detected three EcoRI fragments of 4.0, 2.2, and 2.0 kb on Southern blots. In our study cyclin D1 gene amplification was found in 15 (38%) of the 40 HNSCC samples collected. The degree of amplification varied from two- to 18-fold. We also observed two interesting cases of HNSCC which showed not only gene amplification but also an extra 5.2 kb band on the Southern blot, suggestive of cyclin D1 gene rearrangement (fig 1).
For those patients (total of 19) who underwent surgery from March 1992 to July 1993 and had primary tumors with amplified cyclin D1, only 25% (two out of eight) are alive (table). In contrast, seven of 11 patients (64%) whose tumors did not manifest cyclin D1 gene amplification have survived an average of one and a half years (table).

In order to determine the frequency with which the cyclin D1 gene is overexpressed, we examined the level of cyclin D1 transcription by northern analysis. A major transcript of 4.5 kb as well as a minor one of 1.5 kb were detected with the cyclin D1 probe. Of the 15 HNSCC samples with cyclin D1 amplification, all 13 with available RNA showed increased cyclin D1 expression when compared to their normal mucosa counterparts (fig 2). The overexpression ranged from two- to 16-fold. The two samples with an extra 5-2 kb EcoRI band did not show a dramatic increase in expression of cyclin D1. Despite the fact that cyclin D1 overexpression was found in every case of HNSCC with gene amplification, the degree of amplification and overexpression did not seem to correlate fully. The cyclin D1 mRNA level of the 25 HNSCC samples without gene amplification was also examined. Overexpression of cyclin D1 gene at the mRNA level was not detected in any of the 22 samples from which RNA was available.

Discussion

Our finding of a relatively high percentage (38%) of cyclin D1 gene amplification is consistent with that from another report, in which amplification was recorded in 37% of advanced laryngeal tumours.20 Although rearrangements in the cyclin D1 gene have been shown in parathyroid adenoma4 and centrocyclic lymphoma,56 none has been reported in HNSCC. It would therefore be informative to investigate further the two cases which showed an extra 5.2 kb band on Southern blotting, to establish whether or not the rearrangement was indeed involved in some of the HNSCC cases.

The association between overexpression of cyclin D1 and a shortened overall survival of HNSCC patients has recently been reported in immunohistological studies.32 Our observation, however, suggests a quantitatively significant relationship between prospects for survival and cyclin D1 gene amplification. Although the small sample size precluded statistical significance (p = 0.170 by Fisher’s exact test), the data suggest a trend for HNSCC patients with cyclin D1 gene amplification to be at greater risk of early death than patients who showed no amplification. These results also suggest that cyclin D1 gene amplification may play an important role in the progression of HNSCC and in the clinical outcome. Further studies with larger numbers will be necessary to evaluate the extent of amplification of the cyclin D1 gene in relation to prognosis.

The mechanism by which overexpression of the cyclin D1 gene affects the progression of HNSCC is not well understood. Overexpression may, by itself or in combination with other oncogene products, contribute to increased cellular proliferation.113–37 It has been suggested that increased expression of cyclin D1 may provide a growth advantage for tumour cells because cells overexpressing this protein have a shortened G1 phase and less dependence on growth factors in vitro.18–36

It has also been reported that overexpression of the cyclin D1 gene may induce cellular transformation in cooperation with other oncogenes.12–17 Further, this effect seems to be mediated through the capacity of cyclin D1 to overcome the inhibitory effect of retino-blastoma (RB) protein on cell cycle progression.21 Indeed, it has been found that in oesophageal cancer overexpression of cyclin D1 is associated with persistent expression of RB protein, whereas normal cyclin D1 expression appears to be associated with loss of RB expression.32 In view of these findings, we are currently investigating whether or not expression of RB is altered in HNSCC.38

We thank Ms Liljana Pavelic for collecting the tissues and Nancy Nichols for her secretarial assistance. This work was supported in part by NIH training grant CA 59268 (to XV).

19 Williams ME, Gaughen MJ, Lawrence MW, Wilczynski SP, Schuuring E, Levine PA. Chromosome 11q13 am-

Clin Mol Pathol: first published as 10.1136/mp.48.5.M258 on 1 October 1995. Downloaded from http://mp.bmj.com/ on September 13, 2023 by guest. Protected by copyright.
Cyclin D1 gene amplification in head and neck cancer.

M259


